The objective of this work is to investigate and then to sequence new biomarkers in the plasma of patients presenting with dyspnea secondary or not to heart failure, and study their diagnostic and prognostic value.
Plasma samples for patients with dyspnea, edema, with or without heart failure; ambulatory or admitted for cardiac decompensation (even with cardiac shock and LVAD) ; or entering a cardiac rehabilitation program, will be prospectively collected. The objective of this work is to investigate and then to sequence new proteins in the plasma of these patients for diagnostic and prognostic purpose.
Study Type
OBSERVATIONAL
Enrollment
3,000
Lariboisiere hospital
Paris, Île-de-France Region, France
RECRUITINGLong term cardiovascular mortality
To detect prognostic values of plasma biomarkers, we assess cardiovascular mortality at 3, 6, and 24 months.
Time frame: Prospective at 12 months
Cardiac hospitalization(s) at 3, 6,12 and 24 months
We assess cardiac morbidity within 3, 6, and 24 months months after admission
Time frame: Prospective at 12 months
Diagnostic value of new biomarkers.
Assess accuracy of new biomarkers to discriminate heart failure from non-heart failure (negative and positive predictive values)
Time frame: at day 0
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.